logo-loader
viewVolitionRx

VolitionRx reports positive interim results from Danish colorectal cancer study

Cameron Reynolds, chief executive of VolitionRx Ltd (NYSE:VNRX), discusses with Proactive's Andrew Scott the positive interim results from their trial in Denmark concerning colorectal cancer (CRC), which point to being able to detect early signs of the disease.

The ongoing study is in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program.

Quick facts: VolitionRx

Price: 3.37 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $155.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q1 'very much a building quarter' for VolitionRx with growing cash reserves

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEMKTS:VNRX), discusses with Proactive Investors their Q1 2018 earnings. The company reported a slower first quarter cash burn rate while growing cash reserves. For the period ended March 31, it increased its cash...

on 11/5/18

2 min read